Biodexa Pharmaceuticals Plc
Business
Biodexa Pharmaceuticals Plc is a clinical-stage biopharmaceutical company developing therapies for diseases with unmet medical needs. It develops proprietary therapeutics including eRapa (a nanotechnology-enabled rapamycin formulation), tolimidone (a lyn kinase activator for type 1 diabetes), and MTX110 (a convection-enhanced delivery formulation of panobinostat for rare brain cancers). Its operations include clinical-stage assets supported by three drug delivery technology platforms (Q-Sphera, MidaSolve and MidaCore) focused on sustained delivery and nanoparticle/oligosaccharide technologies. The company conducts clinical development primarily in Europe and in international markets via clinical trials and licensing/distribution channels.
Summary from filing dated 2025-04-11
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-6.38M |
| Total assets | $18.18M |
| Total liabilities | $6.77M |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Biodexa Pharmaceuticals Plc's CIK number?
Biodexa Pharmaceuticals Plc's SEC CIK number is 0001643918 (1643918). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Biodexa Pharmaceuticals Plc's SEC filings?
All of Biodexa Pharmaceuticals Plc's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.